SG11201902599SA - Composition comprising combination of trh analog with arundic acid, and pharmaceutically acceptable salt of arundic acid - Google Patents
Composition comprising combination of trh analog with arundic acid, and pharmaceutically acceptable salt of arundic acidInfo
- Publication number
- SG11201902599SA SG11201902599SA SG11201902599SA SG11201902599SA SG11201902599SA SG 11201902599S A SG11201902599S A SG 11201902599SA SG 11201902599S A SG11201902599S A SG 11201902599SA SG 11201902599S A SG11201902599S A SG 11201902599SA SG 11201902599S A SG11201902599S A SG 11201902599SA
- Authority
- SG
- Singapore
- Prior art keywords
- arundic acid
- composition
- combination
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- YCYMCMYLORLIJX-SNVBAGLBSA-N (2r)-2-propyloctanoic acid Chemical compound CCCCCC[C@H](C(O)=O)CCC YCYMCMYLORLIJX-SNVBAGLBSA-N 0.000 title abstract 3
- 229950005776 arundic acid Drugs 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 title 1
- 208000020358 Learning disease Diseases 0.000 abstract 1
- 206010008118 cerebral infarction Diseases 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 201000003723 learning disability Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 239000003045 protirelin derivative Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/126—Acids containing more than four carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/126—Acids containing more than four carbon atoms
- C07C53/128—Acids containing more than four carbon atoms the carboxylic group being bound to a carbon atom bound to at least two other carbon atoms, e.g. neo-acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/30—Other Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016195505 | 2016-10-03 | ||
JP2017184731 | 2017-09-26 | ||
PCT/JP2017/034926 WO2018066427A1 (ja) | 2016-10-03 | 2017-09-27 | Trhアナログ及びアルンド酸を組み合わせてなる組成物、並びにアルンド酸の薬学的に許容される塩 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201902599SA true SG11201902599SA (en) | 2019-05-30 |
Family
ID=61832036
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201902599SA SG11201902599SA (en) | 2016-10-03 | 2017-09-27 | Composition comprising combination of trh analog with arundic acid, and pharmaceutically acceptable salt of arundic acid |
Country Status (16)
Country | Link |
---|---|
US (1) | US10828303B2 (ja) |
EP (1) | EP3520795B1 (ja) |
JP (2) | JP6596697B2 (ja) |
KR (1) | KR20190065315A (ja) |
CN (2) | CN113559102B (ja) |
AU (1) | AU2017340594B2 (ja) |
BR (1) | BR112019006429A2 (ja) |
CA (1) | CA3039027A1 (ja) |
CO (1) | CO2019003255A2 (ja) |
IL (1) | IL265688A (ja) |
MX (1) | MX2019003837A (ja) |
PH (1) | PH12019500636A1 (ja) |
SG (1) | SG11201902599SA (ja) |
TW (1) | TW201818939A (ja) |
WO (1) | WO2018066427A1 (ja) |
ZA (1) | ZA201902341B (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201907591D0 (en) * | 2019-05-29 | 2019-07-10 | Eolas Res Limited | Composition and use |
IT202000015895A1 (it) | 2020-07-27 | 2022-01-27 | Univ Cattolica Del Sacro Cuore | L’impiego di acido arundico nella terapia della sclerosi multipla |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6223429A (ja) * | 1985-07-24 | 1987-01-31 | Ishikawajima Harima Heavy Ind Co Ltd | 水素同位体の回収・貯蔵・供給装置 |
JPS62234029A (ja) * | 1985-12-27 | 1987-10-14 | Tanabe Seiyaku Co Ltd | 中枢神経賦活剤 |
ATE163006T1 (de) | 1993-06-01 | 1998-02-15 | Ono Pharmaceutical Co | Pentansäurederivate |
JPH0782166A (ja) | 1993-09-14 | 1995-03-28 | Tanabe Seiyaku Co Ltd | 抗ショック剤 |
US9016221B2 (en) * | 2004-02-17 | 2015-04-28 | University Of Florida Research Foundation, Inc. | Surface topographies for non-toxic bioadhesion control |
US7820715B2 (en) * | 2004-04-28 | 2010-10-26 | Ono Pharmaceutical Co., Ltd. | Crystal comprising (2R)-2-propyloctanoic acid and amine |
JP2006143708A (ja) * | 2004-10-19 | 2006-06-08 | Ono Pharmaceut Co Ltd | 神経変性疾患治療用医薬 |
TW202216656A (zh) * | 2008-05-23 | 2022-05-01 | 美商Prtk Spv2公司 | 四環素化合物之甲苯磺酸鹽及同素異形體 |
ES2613059T3 (es) * | 2009-06-16 | 2017-05-22 | Rspr Pharma Ab | Forma cristalina de pemirolast |
CN102786414B (zh) * | 2012-08-15 | 2014-07-16 | 四川大学 | 一类用于治疗和/或预防神经退行性相关疾病的化合物 |
-
2017
- 2017-09-27 CA CA3039027A patent/CA3039027A1/en not_active Abandoned
- 2017-09-27 US US16/338,594 patent/US10828303B2/en active Active
- 2017-09-27 KR KR1020197011464A patent/KR20190065315A/ko not_active Application Discontinuation
- 2017-09-27 BR BR112019006429A patent/BR112019006429A2/pt not_active IP Right Cessation
- 2017-09-27 MX MX2019003837A patent/MX2019003837A/es unknown
- 2017-09-27 CN CN202110788643.7A patent/CN113559102B/zh active Active
- 2017-09-27 CN CN201780072845.3A patent/CN110267661B/zh active Active
- 2017-09-27 WO PCT/JP2017/034926 patent/WO2018066427A1/ja active Application Filing
- 2017-09-27 EP EP17858265.6A patent/EP3520795B1/en active Active
- 2017-09-27 JP JP2018543858A patent/JP6596697B2/ja active Active
- 2017-09-27 SG SG11201902599SA patent/SG11201902599SA/en unknown
- 2017-09-27 AU AU2017340594A patent/AU2017340594B2/en not_active Ceased
- 2017-10-02 TW TW106133988A patent/TW201818939A/zh unknown
-
2019
- 2019-03-22 PH PH12019500636A patent/PH12019500636A1/en unknown
- 2019-03-28 IL IL265688A patent/IL265688A/en unknown
- 2019-04-01 CO CONC2019/0003255A patent/CO2019003255A2/es unknown
- 2019-04-12 ZA ZA2019/02341A patent/ZA201902341B/en unknown
- 2019-07-16 JP JP2019131162A patent/JP2019203007A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN113559102B (zh) | 2023-01-03 |
MX2019003837A (es) | 2019-06-24 |
CN110267661B (zh) | 2021-08-03 |
US10828303B2 (en) | 2020-11-10 |
ZA201902341B (en) | 2020-08-26 |
CN113559102A (zh) | 2021-10-29 |
CA3039027A1 (en) | 2018-04-12 |
CO2019003255A2 (es) | 2019-04-12 |
BR112019006429A2 (pt) | 2019-06-25 |
JP6596697B2 (ja) | 2019-10-30 |
EP3520795A4 (en) | 2020-05-13 |
JPWO2018066427A1 (ja) | 2019-07-25 |
AU2017340594A1 (en) | 2019-04-18 |
US20190240221A1 (en) | 2019-08-08 |
NZ752311A (en) | 2020-12-18 |
TW201818939A (zh) | 2018-06-01 |
CN110267661A (zh) | 2019-09-20 |
WO2018066427A1 (ja) | 2018-04-12 |
AU2017340594B2 (en) | 2020-09-10 |
PH12019500636A1 (en) | 2019-10-28 |
EP3520795A1 (en) | 2019-08-07 |
JP2019203007A (ja) | 2019-11-28 |
KR20190065315A (ko) | 2019-06-11 |
IL265688A (en) | 2019-05-30 |
EP3520795B1 (en) | 2023-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL298689B1 (en) | Preparations and methods for suppressing masp-3 for the treatment of various diseases and conditions | |
EP3526319A4 (en) | METHOD AND COMPOSITIONS AND FOR TREATING DISEASES AND DISORDERS OF THE CENTRAL VENTILATION SYSTEM | |
MX2018013472A (es) | Tratamiento de combinacion de trastornos y enfermedades inflamatorios oculares. | |
MY195948A (en) | Allosteric Modulators of Nicotinic Acetylcholine Receptors | |
PH12016501654A1 (en) | Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders | |
CR20160352A (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
TN2017000144A1 (en) | 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors | |
EP3600349A4 (en) | Colon selective sequestrants for the treatment and prevention of autism and allied diseases | |
SG11202001131TA (en) | Amino acid compositions for the treatment of neuronal injury | |
CR20160394A (es) | Heteroaril amidas como inhibidores de agregación de proteína | |
EP3507371A4 (en) | METHODS AND COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | |
MX2019004859A (es) | Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas. | |
ZA201805407B (en) | Composition for the prevention or treatment of neurodegenerative diseases. | |
EP4054713A4 (en) | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING SKIN DISEASES AND DISORDERS USING LEKTI | |
SG11202004754VA (en) | Compounds for the treatment of neuromuscular disorders | |
SG11201902599SA (en) | Composition comprising combination of trh analog with arundic acid, and pharmaceutically acceptable salt of arundic acid | |
EP3897641C0 (en) | TREATMENT OF MOVEMENT DISORDERS | |
MX2018009662A (es) | Metodo y composicion farmaceutica para tratamiento de neurodegeneracion. | |
MX2016013451A (es) | Heterociclilsulfonas arilo sustituidas. | |
HUE061852T2 (hu) | Dobezilsavat tartalmazó szemészeti topikális kompozíció a szem hátsó szegmense betegségeinek kezelésére | |
PL3694505T3 (pl) | Związek i kompozycja do stosowania w leczeniu profilaktycznym i/lub terapeutycznym chorób ośrodkowego układu nerwowego charakteryzujących się spadkiem plastyczności neuronalnej, w szczególności charakteryzujących się spadkiem plastyczności synaptycznej | |
EP3610879A4 (en) | COMPOSITION OF TREATMENT AND / OR PREVENTION OF ALZHEIMER'S DISEASE | |
EP3568138A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ILLNESSES OR DISORDERS ASSOCIATED WITH MYELIN AND INFLAMMATION | |
FI3752173T3 (fi) | Rhodiolan ja astragaluksen yhdistelmä hermostoa rappeuttavien sairauksien hoitoon | |
BR112018012343A2 (pt) | composições de benzofenonas poli-hidroxiladas e métodos de tratamento de distúrbios neurodegenerativos |